MX2007013133A - Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. - Google Patents
Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b.Info
- Publication number
- MX2007013133A MX2007013133A MX2007013133A MX2007013133A MX2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A MX 2007013133 A MX2007013133 A MX 2007013133A
- Authority
- MX
- Mexico
- Prior art keywords
- apo
- secretion
- compounds
- inhibitors
- transfer protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se relaciona con compuestos los cuales son inhibidores de la proteina microsomal de transferencia de trigliceridos y/o de la secrecion de apolipoproteina B (Apo B). Estos compuestos pueden ser utiles para la prevencion y tratamiento de diversas enfermedades, particularmente ateroesclerosis y sus secuelas clinicas, para disminuir lipidos sericos y afecciones relacionadas. La invencion ademas se relaciona con composiciones farmaceuticas que comprenden los compuestos y con metodos para tratar enfermedades, tales como hipertrigliceridemia, hiperquilomicronemia, ateroesclerosis, obesidad y padecimientos relacionados utilizando los compuestos. Tambien se proporciona un metodo para disminuir la secrecion de apolipoproteina B (apo B).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67277805P | 2005-04-19 | 2005-04-19 | |
US75539005P | 2005-12-30 | 2005-12-30 | |
PCT/US2006/015146 WO2006113910A2 (en) | 2005-04-19 | 2006-04-19 | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007013133A true MX2007013133A (es) | 2008-03-14 |
Family
ID=37115969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007013133A MX2007013133A (es) | 2005-04-19 | 2006-04-19 | Inhibidores de la proteina microsomal de transferencia de trigliceridos de la secrecion de apo-b. |
Country Status (19)
Country | Link |
---|---|
US (2) | US8980915B2 (es) |
EP (1) | EP1877369B1 (es) |
JP (1) | JP5356017B2 (es) |
KR (1) | KR20080015792A (es) |
AU (1) | AU2006236226B2 (es) |
BR (1) | BRPI0607555A2 (es) |
CA (1) | CA2605510C (es) |
CR (1) | CR9528A (es) |
EA (1) | EA024768B1 (es) |
EC (1) | ECSP077913A (es) |
ES (1) | ES2430319T3 (es) |
GE (1) | GEP20104878B (es) |
IL (1) | IL186820A0 (es) |
MX (1) | MX2007013133A (es) |
NI (1) | NI200700272A (es) |
NO (1) | NO20075731L (es) |
NZ (1) | NZ563009A (es) |
SG (1) | SG164371A1 (es) |
WO (1) | WO2006113910A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980915B2 (en) | 2005-04-19 | 2015-03-17 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion |
SG10201406016SA (en) | 2006-04-03 | 2014-11-27 | Stella Aps | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
CA2649045C (en) | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
CA2681406A1 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP3492594A1 (en) | 2007-10-04 | 2019-06-05 | Roche Innovation Center Copenhagen A/S | Micromirs |
AU2009221064B2 (en) | 2008-03-07 | 2014-12-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
WO2010012667A1 (en) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Micro-rna mediated modulation of colony stimulating factors |
ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0481383B1 (en) * | 1990-10-16 | 1995-06-28 | Takeda Chemical Industries, Ltd. | Heterocyclic amine derivatives, their production and use |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
EP1181954A3 (en) * | 1995-06-07 | 2002-08-21 | Pfizer Inc. | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion |
WO1996040640A1 (en) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
DK0832069T3 (da) * | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
NZ330216A (en) | 1996-01-16 | 2000-09-29 | Bristol Myers Squibb Co | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and use in treatment of atherosclerosis |
EP0944602A1 (en) | 1996-11-27 | 1999-09-29 | Pfizer Inc. | Apo b-secretion/mtp inhibitory amides |
IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
US6878707B2 (en) * | 2000-01-18 | 2005-04-12 | Novartis Ag | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
WO2001077077A1 (en) | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
US20050038035A1 (en) * | 2001-11-28 | 2005-02-17 | Hisashi Takasugi | Heterocyclic amide compounds as apolipoprotein b inhibitors |
JP2003231633A (ja) * | 2002-02-06 | 2003-08-19 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2005080373A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
US8980915B2 (en) | 2005-04-19 | 2015-03-17 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion |
-
2006
- 2006-04-19 US US11/407,500 patent/US8980915B2/en active Active
- 2006-04-19 CA CA2605510A patent/CA2605510C/en active Active
- 2006-04-19 JP JP2008507927A patent/JP5356017B2/ja active Active
- 2006-04-19 GE GEAP200610378A patent/GEP20104878B/en unknown
- 2006-04-19 BR BRPI0607555-0A patent/BRPI0607555A2/pt not_active IP Right Cessation
- 2006-04-19 EP EP06751011.5A patent/EP1877369B1/en active Active
- 2006-04-19 NZ NZ563009A patent/NZ563009A/en not_active IP Right Cessation
- 2006-04-19 EA EA200702271A patent/EA024768B1/ru not_active IP Right Cessation
- 2006-04-19 SG SG201005219-9A patent/SG164371A1/en unknown
- 2006-04-19 MX MX2007013133A patent/MX2007013133A/es not_active Application Discontinuation
- 2006-04-19 AU AU2006236226A patent/AU2006236226B2/en not_active Ceased
- 2006-04-19 ES ES06751011T patent/ES2430319T3/es active Active
- 2006-04-19 WO PCT/US2006/015146 patent/WO2006113910A2/en active Application Filing
- 2006-04-19 KR KR1020077026556A patent/KR20080015792A/ko not_active Application Discontinuation
-
2007
- 2007-10-19 NI NI200700272A patent/NI200700272A/es unknown
- 2007-10-21 IL IL186820A patent/IL186820A0/en unknown
- 2007-11-09 NO NO20075731A patent/NO20075731L/no not_active Application Discontinuation
- 2007-11-16 CR CR9528A patent/CR9528A/es not_active Application Discontinuation
- 2007-11-19 EC EC2007007913A patent/ECSP077913A/es unknown
-
2015
- 2015-03-17 US US14/660,453 patent/US9656960B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20080015792A (ko) | 2008-02-20 |
IL186820A0 (en) | 2008-02-09 |
US9656960B2 (en) | 2017-05-23 |
US20070027183A1 (en) | 2007-02-01 |
EA200702271A1 (ru) | 2008-04-28 |
CR9528A (es) | 2008-05-21 |
SG164371A1 (en) | 2010-09-29 |
ECSP077913A (es) | 2008-01-23 |
EP1877369B1 (en) | 2013-07-10 |
EP1877369A4 (en) | 2010-04-14 |
NO20075731L (no) | 2008-01-17 |
WO2006113910A2 (en) | 2006-10-26 |
GEP20104878B (en) | 2010-01-11 |
NZ563009A (en) | 2011-05-27 |
AU2006236226A1 (en) | 2006-10-26 |
EA024768B1 (ru) | 2016-10-31 |
ES2430319T3 (es) | 2013-11-20 |
AU2006236226B2 (en) | 2012-07-05 |
JP2008538568A (ja) | 2008-10-30 |
US8980915B2 (en) | 2015-03-17 |
CA2605510C (en) | 2013-12-24 |
EP1877369A2 (en) | 2008-01-16 |
WO2006113910A3 (en) | 2007-03-22 |
NI200700272A (es) | 2008-07-11 |
US20160039765A1 (en) | 2016-02-11 |
CA2605510A1 (en) | 2006-10-26 |
JP5356017B2 (ja) | 2013-12-04 |
BRPI0607555A2 (pt) | 2009-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG164371A1 (en) | Inhibitors of microsomal triglyceride transfer protein and apo-b secretion | |
EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
GEP20063720B (en) | Triamide-Substituted Indoles, Benzofuranes and Benzothiophenes as Inhibitors of Microsomal Triglyceride Transfer Protein (MTP) and/or Apolipoprotein B (Apo B) Secretion | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
WO2004046120A3 (en) | Diaminotriazoles useful as inhibitors of protein kinases | |
ZA200901037B (en) | Pyrimidone compounds as GSK-3 inhibitors | |
MX2009008099A (es) | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. | |
DE602005007717D1 (de) | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen | |
WO2008127682A3 (en) | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor | |
NO20083918L (no) | Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser | |
NO20072567L (no) | Triazoler nyttige som proteinkinase-inhibitorer | |
PL377713A1 (pl) | Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu | |
EA200802054A1 (ru) | Ингибиторы фермента | |
EA200801008A1 (ru) | Гипохолестеринемические соединения | |
MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
BR0317323A (pt) | Inibidores de proteìna de transferência de triglicerìdeos microssomal | |
BR0317426A (pt) | Inibidores de proteìna de transferência de triglicéridos microssomais | |
EA200700479A1 (ru) | Соединения 4-аминозамещённого-2-замещённого-1,2,3,4-тетрагидрохинолина | |
IL172018A0 (en) | Enalapril-nitroxyderivatives derivatives and related compounds as ace inhibitors for the treatment of cardiovascular diseases | |
ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |